LON:BVX BiVictriX Therapeutics (BVX) Share Price, News & Analysis → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free BVX Stock Alerts GBX 12 +0.50 (+4.35%) (As of 08:44 AM ET) Add Compare Share Share Today's Range 12▼ 1250-Day Range 10.50▼ 1252-Week Range 9▼ 16Volume67 shsAverage Volume53,246 shsMarket Capitalization£9.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get BiVictriX Therapeutics alerts: Email Address Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WayNanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront!See how with its ongoing expansion and development About BiVictriX Therapeutics Stock (LON:BVX)BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.Read More BVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVX Stock News HeadlinesMay 8, 2024 | americanbankingnews.comBiVictriX Therapeutics (LON:BVX) Shares Up 4.3%April 17, 2024 | investing.comBiVictriX Therapeutics PLC (BVX)February 15, 2024 | finance.yahoo.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Turn A Profit?December 6, 2023 | proactiveinvestors.comBiVictriX Therapeutics' former chair moves onOctober 12, 2023 | reuters.comBRIEF-Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid LeukaemiaOctober 12, 2023 | proactiveinvestors.comBiVictriX says latest preclincial leukaemia data could accelerate progressOctober 6, 2023 | finance.yahoo.comBiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing effortsSeptember 20, 2023 | finance.yahoo.comBiVictriX Therapeutics "looking really healthy" after positive first halfSeptember 20, 2023 | finance.yahoo.comBiVictriX Therapeutics to "continue seeking out positive relationships"September 20, 2023 | finance.yahoo.comMarket Sentiment Around Loss-Making BiVictriX Therapeutics Plc (LON:BVX)September 20, 2023 | finance.yahoo.comBiVictriX Therapeutics passes "exciting milestone" with US patent for BVX001September 20, 2023 | finance.yahoo.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Become Profitable?See More Headlines Receive BVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiVictriX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:BVX CUSIPN/A CIKN/A Webwww.bivictrix.com PhoneN/AFaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.06% Return on Assets-38.21% Debt Debt-to-Equity Ratio14.51 Current Ratio6.85 Quick Ratio7.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 5.45 per share Price / Cash Flow2.20 Book ValueGBX 4 per share Price / Book3.00Miscellaneous Outstanding Shares82,530,000Free FloatN/AMarket Cap£9.90 million OptionableNot Optionable Beta-0.60 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Tiffany Jane Thorn BSc. MSc. (Age 37)M.Sc., CEO & Executive Director Comp: $192.5kDr. Adrian Howd Ph.D. (Age 53)Chief Business Officer & CFO Simon WallworkSecretaryKey CompetitorsImmuPharmaLON:IMMGenflow BiosciencesLON:GENFSynairgenLON:SNGRoquefort TherapeuticsLON:ROQRealm TherapeuticsLON:RLMView All Competitors BVX Stock Analysis - Frequently Asked Questions How have BVX shares performed in 2024? BiVictriX Therapeutics' stock was trading at GBX 10.50 at the start of the year. Since then, BVX shares have increased by 14.3% and is now trading at GBX 12. View the best growth stocks for 2024 here. How do I buy shares of BiVictriX Therapeutics? Shares of BVX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:BVX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDoes this make you sick?Allegiance Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiVictriX Therapeutics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
